Six days before 100 percent tariffs hit patented medicines, three of the world’s biggest drugmakers still have no onshoring deal, generic makers have a new 200 percent deadline of their own, and the US drug supply chain is bracing for the most expensive week in its history
WASHINGTON, July 25, 2026
The most consequential tariff deadline of the summer is not the one that expired Friday. It arrives next Friday, July 31, when 100 percent Section 232 duties on patented pharmaceuticals take effect for the 17 largest drug companies serving the American market, and as of this weekend, three of those companies, Pfizer, Johnson & Johnson and GlaxoSmithKline, still have no confirmed agreement with the Commerce Department that would spare them the full rate.
The stakes are difficult to overstate. Pharmaceuticals are among the largest categories of US imports, prescription drug spending in the United States reached 915 billion dollars in 2025 and is projected to cross 1 trillion dollars this year, and a Commerce Department finding underpinning the tariffs concluded that approximately 53 percent of patented pharmaceuticals distributed domestically are produced abroad. A doubling of the border price on even a fraction of that flow would ripple through insurers, hospital formularies, federal health programs and, eventually, patients.
This week the picture grew more complicated still. President Trump announced Tuesday that generic drugs, until now exempt, will face their own tariff wall on a delayed fuse: zero percent for two years, then 100 percent from August 2028, then 200 percent from August 2029. And Friday’s separate imposition of forced labor tariffs on 60 trading partners, while largely exempting medicines, confirmed that pharmaceutical supply chains sit inside a trade environment that is being redesigned wholesale, sector by sector, deadline by deadline.
How the Industry Got to the Edge of the Cliff
The pharmaceutical tariff regime traces to a proclamation President Trump signed on April 2, invoking Section 232 of the Trade Expansion Act of 1962, the national security statute previously used for steel, aluminum, copper and semiconductors. The proclamation imposed a 100 percent ad valorem tariff on patented pharmaceutical products and their active pharmaceutical ingredients, with two effective dates: July 31, 2026 for the 17 large companies named in Annex III of the order, and September 29, 2026 for everyone else.
But the order was never designed to function as a simple tax. It is, as supply chain intelligence firm Exiger described it in a client alert, a compliance mechanism. Companies that sign a Commerce-approved onshoring agreement, committing to build US manufacturing capacity, qualify for a reduced 20 percent rate, which escalates back to 100 percent by April 2030 if reshoring stalls. Companies that pair an onshoring agreement with a most-favored-nation drug pricing agreement with the Department of Health and Human Services qualify for a zero percent rate through January 20, 2029. Separate carve-outs apply by geography and product: goods from the EU, Japan, South Korea, Switzerland and Liechtenstein face a 15 percent ceiling under existing trade framework agreements, United Kingdom products face 10 percent, falling to zero under the December 2025 US-UK pharmaceutical pricing arrangement, and orphan drugs, cell and gene therapies, plasma-derived therapies, fertility treatments and medical countermeasures can qualify for zero.
The design produced a stampede toward Washington. Of the 17 Annex III companies, 14 have now executed the full pairing of Commerce onshoring agreements and HHS pricing deals, locking in the zero rate: a roster that includes Eli Lilly, Novo Nordisk, AbbVie, Merck, Novartis, Sanofi, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, EMD Serono, Genentech, Gilead and, since its April 23 agreement, Regeneron.
That leaves the holdouts. Pfizer, Johnson & Johnson and GlaxoSmithKline, including its ViiV Healthcare joint venture, have each reported drug pricing deals with HHS, but none had a confirmed Commerce onshoring agreement as of the most recent public accounting, and the zero percent pathway explicitly requires both. Commerce published formal procedures for the three companies to apply, with a June 12 application deadline that has come and gone without an announced agreement. Unless deals land in the next six days, products from three of the largest pharmaceutical companies in the world become subject to 100 percent duties at the US border on Friday.
A Deadline Designed for Leverage
Veterans of this administration’s trade policy note that the White House has repeatedly set delayed implementation dates with devastating consequences as a means of creating leverage, and that previous pharmaceutical deadlines have moved. Bloomberg’s reporting this week observed that most of the world’s biggest drugmakers, including Merck and Eli Lilly, sidestepped the punitive rates by striking agreements, which is precisely the outcome the structure was built to produce.
Ryan Last, a senior associate at the law firm Troutman Pepper Locke who advises pharmaceutical companies on the tariffs, told Pharmaceutical Executive that the window for hesitation has closed. “If you’re even considering an onshoring agreement, the time for conceptual discussions has passed,” he said, adding that companies need concrete, data-backed proposals covering which products are clinically critical, which are realistically able to be onshored, and how regulatory, manufacturing, supply chain and quality functions will execute the transition.
Last also offered a measure of how much capital the pressure campaign has already mobilized. “So far, what we’re seeing, based on calls I’ve had with multiple large organizations and clients, is that the industry is committing over 500 billion dollars in US investment, which is more than what we expected when the Section 232 tariffs were announced,” he said. “We’re seeing facilities starting construction, but in the end, shifting supply chains and building these facilities is not something that happens overnight.”
The announced commitments are indeed enormous. Johnson & Johnson has pledged 55 billion dollars in US investment over four years. Roche announced 50 billion over five years. AstraZeneca committed 50 billion through 2030. Novartis pledged 23 billion. Eli Lilly’s LEAP campus in Lebanon, Indiana has swollen past 13 billion dollars with successive expansions. Novo Nordisk added a 4.1 billion dollar expansion of its North Carolina fill-finish facility. The administration cites this construction boom as vindication. Skeptics note that pharmaceutical-grade manufacturing capacity typically takes five to ten years to build and validate, which means the tariffs will bite long before the factories they are meant to summon can produce a single tablet.
The Generics Reprieve Now Has an Expiration Date
Until this week, makers of generic drugs, which fill roughly 90 percent of US prescriptions, could take comfort in their exemption from the April proclamation, subject to a mandatory reassessment within twelve months. On Tuesday, the president resolved the suspense himself. Generic manufacturers will have two years to move production to the United States or face a 100 percent import duty from August 2028, doubling to 200 percent in August 2029, he announced in a social media post.
“This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them,” Trump wrote, in the post reported by Bloomberg.
The generics industry has far less cushion than the branded sector. Generic manufacturers compete on thin margins across global manufacturing networks, and cannot absorb triple-digit duties the way a patent-protected franchise might. Richard Saynor, chief executive of Sandoz, one of the world’s largest generic producers, warned last year that steep US tariffs would likely make drugs more expensive and limit access for patients. Sandoz, Teva and Viatris, the three giants of the sector, all manufacture heavily outside the United States, in locations from Canada and Austria to India and Israel.
The country with the most at stake is India, the biggest exporter of generic medicines to the United States. Pharmaceuticals rank among India’s top three exports to America, totaling 10.5 billion dollars in the 2024-25 fiscal year according to India’s Commerce Ministry, and Bloomberg calculates that duties on drugs would leave over 40 percent of India’s US-bound exports adversely affected when combined with existing levies. The dependence runs deep into the American medicine cabinet: an earlier Bloomberg analysis of Symphony Health data found that roughly 65 percent of all birth control pill prescriptions in the US in 2024 were manufactured by just two India-based companies, Glenmark Pharmaceuticals and Lupin. India’s February trade pact with Washington stipulates that India would receive negotiated outcomes with respect to generic pharmaceuticals and ingredients, language whose practical meaning will now be tested. Notably, Friday’s forced labor tariffs explicitly exempted generic pharmaceuticals from India, a signal that Washington intends to keep the generics question inside the Section 232 track and the bilateral negotiation rather than let it bleed into other tariff actions.
The Politics of the Pharmacy Counter
The tariff architecture cannot be separated from the administration’s drug pricing agenda, because the two are formally fused. The zero percent tariff pathway requires a most-favored-nation pricing agreement with HHS, under which a company commits to selling drugs in the United States at prices no higher than those charged in other wealthy countries. The president has long complained about Americans paying more than Europeans for identical medicines, and the tariff serves as the enforcement mechanism that decades of legislative proposals never supplied. The administration has paired the pressure campaign with TrumpRX, a direct-to-consumer discount drug platform launched to showcase the negotiated prices.
The political timing is not subtle. Drug costs consistently rank among voters’ top affordability concerns, and the administration has seized on pharmaceutical prices as a signature issue heading into the November midterm elections. Every onshoring agreement announcement doubles as a jobs announcement, and every MFN pricing deal doubles as a cost-of-living announcement. That dual politics explains why the administration has been willing to extend and restructure deadlines for companies that engage, while showing little patience for those that hold out.
It also explains the sequencing of the generics decision. Imposing immediate duties on generic drugs, which supply nine of every ten American prescriptions at commodity prices, would have produced visible pharmacy-counter inflation within months, an outcome no administration wants in an election year. The two-year fuse defers the cost while preserving the reshoring pressure, and the escalation to 200 percent in 2029 pushes the most painful scenario safely past the next presidential election. Whether generic manufacturers can actually build compliant US capacity on that timeline is another question entirely; industry executives note that even a straightforward oral solid dose facility takes years to construct, validate and clear FDA inspection.
September 29 and the Long Tail of Smaller Companies
While the spotlight stays on the Annex III giants, trade advisers say the more dangerous exposure may sit with the hundreds of companies facing the September 29 effective date. Smaller and mid-size pharmaceutical companies confront the same 100 percent default rate but lack the negotiating leverage, the Washington relationships and the capital to secure company-specific agreements. Exiger’s analysis of shipment records found substantial branded pharmaceutical volumes from manufacturers outside Annex III that remain fully exposed, concentrated in specialty injectables, hormone therapies, plasma-derived biologics and contract manufacturing organizations, with production rooted in Germany, Switzerland, Ireland and Belgium, geographies whose regulatory infrastructure cannot be relocated on any near-term schedule.
For those companies, the practical options narrow to a handful: qualify for a product-level carve-out in categories such as orphan drugs or cell and gene therapies, restructure supply chains to route production through US sites or exempt jurisdictions, absorb the duty and attempt to pass it through pricing, or exit the US market. Each option carries clinical consequences. Specialty drugs with limited manufacturing alternatives are precisely the products where supply disruption translates most directly into patient harm, and hospital pharmacists have warned throughout the year that sterile injectables, already the most shortage-prone category in the US drug supply, sit squarely in the exposure zone.
What 100 Percent Duties Would Do to Drug Costs
The industry’s central argument against the tariffs is that they tax inputs America cannot quickly replace. PhRMA, the branded industry’s trade association, warned when the tariffs were announced that “tariffs on cutting-edge medicines will increase costs and could jeopardize billions in U.S. investments announced in the last year,” in the words of its president and chief executive, Stephen Ubl. The association points out that foreign sourcing of innovative drugs comes overwhelmingly from allied nations in Europe and Japan rather than adversaries, a fact it argues undermines the national security rationale.
The exposure does not stop at finished medicines. Domestically manufactured drugs that rely on foreign-origin active ingredients face tariff liability at the ingredient level. FDA data show that as of 2025 only 11 percent of API manufacturing facilities supplying the US market are US-based. A study in Health Affairs Scholar modeled the consequence and found that a 100 percent API tariff would add an average of 21.15 dollars per prescription for domestically produced drugs using imported ingredients, a cost that thin-margin manufacturers are unlikely to absorb.
Patient advocates raised alarms the day the proclamation was signed, warning that costs would flow through to payers, insurers and patients. The federal government itself carries outsized exposure: it is the single largest purchaser of prescription drugs in the country through the Departments of Veterans Affairs and Defense and federal health programs, and fixed-price contracts signed before April 2 may lack economic price adjustment clauses adequate to absorb a doubling of supplier costs. Analysts at Exiger have advised agencies and prime contractors sourcing from Pfizer, Johnson & Johnson or GlaxoSmithKline to review supply agreements for price adjustment provisions, substitution rights and force majeure language before the enforcement window opens.
Payers are already modeling the pass-through. Pharmacy benefit managers have circulated scenario analyses to plan sponsors assuming partial tariff pass-through beginning in the fourth quarter, concentrated in specialty and biologic categories where the three unresolved manufacturers hold dominant franchises. Hospital systems, whose margins have little room for input shocks, warn that a doubling of acquisition costs on even a narrow band of clinically essential products would force painful formulary decisions. And insurers point out that premium filings for 2027 are being drafted now, meaning tariff costs that materialize next week will be priced into coverage months before any onshored production exists to offset them.
There is also a stockpiling dynamic already visible in trade data. Shipment records show branded drug and API imports spiking in mid-2025 as companies front-loaded inventory ahead of anticipated tariffs, followed by a sharp demand trough as buyers worked through their buffers. Many of those buyers are now re-entering the market on normal procurement cycles, directly into the tariff environment the stockpiling was designed to avoid.
The Week Ahead, and What Businesses Should Do
The next six days will resolve the most immediate question: whether Pfizer, Johnson & Johnson and GSK close onshoring agreements before the deadline, negotiate an extension, or begin paying triple-digit duties on products from insulin-adjacent biologics to HIV therapies. History argues for a last-minute resolution; the administration’s pattern has been to convert deadlines into deals. But nothing in the published record guarantees one, and companies downstream of the three holdouts cannot plan on hope.
For importers, distributors, pharmacy benefit managers and health systems, trade advisers are converging on a consistent playbook. Map exposure to the supplier and manufacturing-site level, because a drug assembled in Ireland from Chinese-origin ingredients carries risk at multiple tiers, and tariff liability follows where products and ingredients are actually made, not where the label says. Watch the full spread of affected tariff classifications, from finished medicaments under HS heading 3004 to hormones and GLP-1 agonists under 2937 and the small-molecule API chapters. Audit contracts for price adjustment and substitution rights. And treat the generics exemption as temporary, because it now formally is: the two-year clock to August 2028 started this week, and the Section 232 reassessment of the generics carve-out remains due by April 2027.
Health systems and group purchasing organizations face their own version of the deadline. Formulary committees that began evaluating therapeutic substitutions in the spring now have days, not months, to decide whether to lock in orders from exposed manufacturers, shift volume toward the fourteen zero-rate companies, or accept pass-through pricing clauses that distributors have been inserting into contracts all summer. Selective stockpiling of the highest-risk categories is defensible, advisers say, but only if coordinated, because a rush of precautionary buying can itself trigger the shortages it is meant to insure against.
The regulatory calendar beyond Friday offers little rest. September 29 brings the enforcement window for every branded manufacturer outside Annex III. The twelve-month reassessment of the generics exemption, which runs from the April 2 proclamation, is due by April 2027, and the criteria remain unpublished, though the administration’s focus on Chinese and Indian API concentration gives a strong hint of where the review will land. The 20 percent onshoring rate begins escalating toward 100 percent in April 2030. And the US-UK pharmaceutical pricing arrangement, which zeroes out duties on British products, remains conditional on major UK companies entering MFN agreements, a condition still being worked through company by company.
The larger story is that the United States is running an unprecedented industrial policy experiment on the medicine supply of 330 million people, using tariff deadlines as the forcing mechanism and company-by-company agreements as the instrument. Fourteen of seventeen giants have already taken the deal, committing hundreds of billions of dollars in domestic investment along the way. Whether the last three sign by Friday, and whether the factories rise before the duties bite, will determine if the experiment is remembered as the policy that reshored the pharmacy, or the one that made it unaffordable.